Neurology · AntiepilepticRegulatory Approvalcommercialmid-term

Granules' Lamotrigine ANDA078982 Receives Approval Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:32:37 PM

Assessment confidence: 72% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The Approval Pending status for Granules' Lamotrigine indicates a significant shift in the competitive landscape for this generic product. Pharma strategy teams should assess the implications for pricing and market share as Granules prepares to enter the market. Regulatory context from FDA (FDA AP — LAMOTRIGINE (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the potential market entry of Granules' Lamotrigine and its impact on existing products. The strongest clinical anchor is The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antiepileptic, 7 regulatory and 5 competitive items passed relevance filtering for Granules.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status indicates Granules is advancing in the competitive landscape for generic Lamotrigine, which may impact pricing and market share.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LAMOTRIGINE (SUPPL) (FDA). Entity match (granules); Regulatory pathway relevance (nda). While the Approval Pending status suggests progress, the final approval decision will be critical for market entry and compliance with regulatory standards.

Key Risks

Elevated medium regulatory exposure for Granules could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Granules through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Granules into the Lamotrigine market could lead to increased competition, potentially driving down prices and affecting the revenue of existing competitors.
Portfolio teams should evaluate the potential market entry of Granules' Lamotrigine and its impact on existing products.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval decision and market launch timelines for Lamotrigine from Granules.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (granules); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View source

The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Quality of Life in Patients Who Have Undergone Stem Cell Transplant
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Restraints in Intensive Care Unit Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Sandoz Receives FDA Approval for Liraglutide ANDA212972
Humanexa Signalsmedium relevance
Moderate corpus alignment

The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Granules
Lamotrigine
existing competitors

Commercial impact

medium

The entry of Granules into the Lamotrigine market could lead to increased competition, potentially driving down prices and affecting the revenue of existing competitors.

Regulatory impact

medium

While the Approval Pending status suggests progress, the final approval decision will be critical for market entry and compliance with regulatory standards.

What to watch

Monitor the final approval decision and market launch timelines for Lamotrigine from Granules.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.